Lupus News

ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting.

Although chimeric antigen receptor T-cell therapy has delivered previously unthinkable remission outcomes to patients with lupus and other rheumatic diseases, the cells currently in use remain “old fashioned,” according to a speaker.

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has several limitations that may be overcome instead through bispecific T-cell-engaging antibodies, according to a speaker.

Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that impact quality of life, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Black patients, particularly women, have died from systemic lupus erythematosus at disproportionately higher rates despite overall declines in mortality over the past 20 years, according to data published in Arthritis Care & Research.

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal response, according to data published in The New England Journal of Medicine.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell therapy that may bypass lymphodepletion, paving the way for a phase 1 trial in lupus and other autoimmune diseases.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Twelve years is a long time by most measures, but in a field has rapidly changing as lupus nephritis research, it may as well be an eternity.